Last Day of Trading in Warrants Series TO 9: Alligator Bioscience's Strategic Move

As the last day of trading in warrants series TO 9 in Alligator Bioscience AB approaches on 13 December 2024, investors are evaluating the potential impact of this strategic move on the company's future. Alligator Bioscience, a clinical-stage biotechnology company focused on tumor-directed immuno-oncology antibody drugs, carried out a rights issue of units during March - April 2024, which included one ordinary share and one warrant series TO 9. The subscription price for the warrants was set at 90 percent of the volume-weighted average price (VWAP) of the Company's ordinary share on Nasdaq Stockholm during the period 4 - 29 November 2024, amounting to SEK 0.55 per share.

The exercise period for the warrants is from 4 December 2024 to 18 December 2024, with the last day for trading in the warrants being 13 December 2024. Holders of warrants who wish to exercise these to subscribe for ordinary shares must give notice regarding such exercise at the latest on 18 December 2024. Warrants that have not been exercised on or before 18 December 2024 will expire without value. Holders who do not wish to exercise their warrants may sell them on Nasdaq Stockholm under the short name ATORX TO 9 and with ISIN code SE0021629557.

Upon full exercise of all 100,084,946 warrants series TO 9, the share capital will increase by a maximum of SEK 80,067.9568 to SEK 687,259.2256 through the issuance of a maximum of 100,084,946 new ordinary shares. This will result in the total number of outstanding shares in the Company increasing from 758,989,086 to 859,074,032, whereof 858,124,182 are ordinary shares and 949,850 are series C shares. The dilution of the ordinary shares will amount to approximately 11.7 percent, with the total number of votes in the Company amounting to 858,219,167 following full exercise of all warrants TO 9.

If all warrants are exercised, Alligator will receive approximately SEK 55.0 million before issue costs, which can be used to support ongoing research and development, potentially leading to innovative treatments and increased market value in the long run. However, investors should monitor the company's financial health and future financing needs to ensure that dilution remains a viable strategy for growth.

In conclusion, the last day of trading in warrants series TO 9 in Alligator Bioscience AB is an important milestone for the company, as it allows investors to capitalize on the potential benefits of the rights issue and the company's strategic focus on immuno-oncology antibody drugs. The exercise of these warrants will have a significant impact on the company's share capital, dilution, and overall market capitalization, making it a crucial event for investors to consider.